Drugs Containing Excipient (Inactive Ingredient) CROSCARMELLOSE

« Back to Dashboard

Branded drugs containing CROSCARMELLOSE excipient, and estimated key patent expiration / generic entry dates

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Eli Lilly and Company	INLURIYO	imlunestrant	0002-1717	CROSCARMELLOSE SODIUM	2030-09-25
Eli Lilly and Company	OLUMIANT	baricitinib	0002-4182	CROSCARMELLOSE SODIUM
Eli Lilly and Company	REYVOW	lasmiditan	0002-4312	CROSCARMELLOSE SODIUM	2040-07-06

Generic drugs containing CROSCARMELLOSE excipient

Company	Ingredient	NDC	Excipient
QPharma Inc	ranitidine	42708-118	CROSCARMELLOSE
Sun Pharmaceutical Industries Inc	risedronate sodium	47335-666	CROSCARMELLOSE
Aidarex Pharmaceuticals LLC	ranitidine	53217-343	CROSCARMELLOSE

Croscarmellose Sodium Market Dynamics and Financial Trajectory

Last updated: October 10, 2026

Croscarmellose sodium is a high-value pharmaceutical disintegrant used mainly in immediate-release tablets and hard capsules. Demand is tied to generic drug production, oral solid-dose volume, direct-compression manufacturing, and regulatory preference for established compendial excipients. The market is structurally resilient but price competitive. Suppliers typically generate better margins from controlled grades, technical support, qualification services, and global supply reliability than from commodity volume alone.

Standalone revenue for croscarmellose sodium is not generally disclosed by manufacturers. Public-company filings report broader pharmaceutical-excipient or health-and-nutrition segments rather than product-level sales. The financial trajectory therefore depends on volume growth, grade mix, regional expansion, capacity utilization, and pricing discipline rather than a transparent public market forecast.

What is croscarmellose sodium and how is it used?

Croscarmellose sodium is a cross-linked, internally carboxymethylated cellulose used primarily as a superdisintegrant. It promotes tablet breakup by absorbing water and expanding within the dosage form.

The excipient is used in:

• Immediate-release tablets
• Orally disintegrating and fast-dissolving tablets
• Hard gelatin and HPMC capsules
• Direct-compression formulations
• Wet-granulated tablets
• Some chewable and multiparticulate dosage forms

Its commercial value comes from efficient use at relatively low concentrations, usually about 0.5% to 5% of the formulation, depending on tablet composition and performance targets. The required level depends on compression force, lubricant concentration, granulation method, tablet porosity, active pharmaceutical ingredient properties, and dissolution specifications.

Croscarmellose sodium is listed in major pharmacopeias, including the United States Pharmacopeia-National Formulary, European Pharmacopoeia and other regional standards. Its regulatory identity is generally established through compendial specifications and supplier documentation rather than through a product-specific drug approval. [1]

How large is the croscarmellose sodium market?

No authoritative public source provides a consistently defined global revenue figure for croscarmellose sodium alone. Commercial market reports often combine croscarmellose sodium with other superdisintegrants, pharmaceutical excipients, cellulose derivatives, or tablet excipients. Reported totals can differ substantially depending on whether the scope includes food, nutraceutical, veterinary and industrial grades.

The market is best analyzed through its demand base:

Market driver	Effect on croscarmellose sodium demand
Generic tablet launches	Increases unit volume and supplier qualification activity
Growth in oral solid dosage forms	Expands recurring consumption
Direct compression	Supports demand for engineered, high-functionality grades
Fixed-dose combinations	Increases formulation complexity and disintegration testing
Emerging-market access programs	Raises demand for cost-efficient excipients
ODT and fast-dissolving products	Supports premium performance grades
Biologics growth	Limited direct benefit because most biologics use injectable delivery
Drug shortages and supply diversification	Increases interest in dual sourcing and regional inventory

The market is volume-driven rather than innovation-driven. Tablet production growth creates recurring demand, but unit pricing is constrained by generic-drug economics. Premium pricing is more defensible when the supplier can demonstrate consistent particle morphology, water uptake, compactability, low variability and reliable lot-to-lot performance.

Which companies supply croscarmellose sodium?

The principal commercial suppliers include IFF, JRS Pharma, DFE Pharma, Roquette and regional manufacturers serving China, India and other Asian markets. Product names and corporate ownership can change through acquisitions, divestitures or portfolio transfers.

Supplier	Representative product or brand	Commercial positioning
IFF	Avicel and Ac-Di-Sol product families, depending on grade and portfolio	Global excipient platform, technical support and multinational supply
JRS Pharma	VIVASOL	Cellulose-based excipient specialization and global formulation support
DFE Pharma	Primellose	Superdisintegrant portfolio and generic-drug formulation support
Roquette	Microcrystalline cellulose and related excipient portfolio	Broad oral solid-dose platform, with competitive cellulose offerings
Regional manufacturers	Multiple non-global brands	Cost competition, local supply and regional regulatory support

The exact availability of a branded croscarmellose sodium grade depends on market, manufacturing site, distributor arrangements and current portfolio ownership. Supplier qualification requires confirmation of the applicable product name, manufacturing location, compendial status, regulatory package and change-control policy.

How does supplier concentration affect pricing?

The market has meaningful supplier concentration at the multinational level, but it is not a single-source market globally. Large pharmaceutical companies generally qualify more than one source where formulation and regulatory filings permit it. Switching suppliers can still be expensive because the change may require:

• Comparative excipient testing
• Tablet performance studies
• Stability data
• Updated regulatory documentation
• Customer-specific validation
• Manufacturing-process requalification

This switching cost gives established suppliers some pricing protection. The protection is weaker for high-volume generic products where procurement teams can qualify lower-cost regional alternatives.

What is the financial trajectory for croscarmellose sodium?

The likely financial trajectory is moderate volume growth with mixed pricing and margin performance.

Base-case market outlook

Period	Expected market condition	Financial implication
Near term	Stable demand from generic tablets and capsules	Revenue growth primarily from volume and mix
Medium term	Continued oral solid-dose growth in emerging markets	Positive unit growth, but price competition remains
Longer term	More differentiated grades and regional manufacturing	Premium grades gain share while standard grades face pricing pressure

Revenue growth is likely to track global pharmaceutical manufacturing growth rather than prescription-drug prices. The strongest demand should come from generic manufacturers, contract development and manufacturing organizations, and emerging-market producers expanding tablet capacity.

Input costs include cellulose feedstock, sodium hydroxide, processing chemicals, energy, labor, packaging, testing and freight. Margins can contract when suppliers cannot pass through increases in energy, logistics or cellulose costs. Pharmaceutical customers often accept price increases more readily when supported by documented cost changes and supply-risk analysis, but annual procurement negotiations limit pass-through.

What determines supplier profitability?

Profitability depends on five variables:

1. Manufacturing scale and plant utilization
2. Product mix between standard and engineered grades
3. Regional freight and inventory costs
4. Regulatory and quality-system efficiency
5. Customer retention after formulation qualification

A plant operating below efficient utilization can experience weak margins even when demand is stable. Conversely, a qualified global grade with strong customer retention can produce attractive recurring revenue because excipient consumption repeats with every batch of the drug product.

Suppliers with broader portfolios can bundle croscarmellose sodium with microcrystalline cellulose, crospovidone, starch derivatives, lubricants and formulation services. This increases customer share and reduces dependence on a single excipient category.

What formulations are protected by croscarmellose sodium?

Croscarmellose sodium itself generally does not provide a broad, standalone patent barrier around ordinary use in tablets. The material is a known compendial excipient with long-established pharmaceutical applications.

Patent protection may attach to:

• A specific drug formulation containing croscarmellose sodium
• A defined concentration range
• A particular particle-size distribution
• A combination with another disintegrant
• A manufacturing process
• A controlled-release or immediate-release profile
• A dosage form using a specific compression or granulation process

The relevant patents usually belong to the drug-product sponsor, not the excipient manufacturer. A branded drug may list formulation or method-of-use patents in the FDA Orange Book, but the listing identifies the approved drug product and associated patents. It does not create an Orange Book patent estate for croscarmellose sodium as a material. [2]

Does croscarmellose sodium have Orange Book or regulatory exclusivity?

Croscarmellose sodium has no independent Orange Book exclusivity. The FDA Orange Book covers approved drug products and certain patents submitted by their sponsors. Excipients are reviewed as components of drug products, not as independently approved active ingredients. [2]

Regulatory relevance arises through:

• FDA inactive-ingredient database entries
• USP-NF monograph compliance
• Drug Master Files or equivalent confidential quality packages
• Certificates of analysis
• Good Manufacturing Practice systems
• Supplier qualification and change-control procedures

The FDA Inactive Ingredient Database provides precedent for excipient use by route, dosage form and maximum potency, but it does not function as an excipient patent register. [3]

European regulatory review is similarly product-focused. The European Medicines Agency has issued guidance on excipient quality and pharmaceutical development, while the European Pharmacopoeia establishes relevant compendial standards. [4]

What patent litigation and Paragraph IV risks affect the market?

Croscarmellose sodium is rarely the central subject of Paragraph IV litigation. Paragraph IV certifications apply to abbreviated new drug applications challenging patents listed for a reference drug. The dispute normally concerns the drug substance, drug formulation, method of use or dosage form.

Croscarmellose sodium can become relevant when:

• A formulation patent claims a specific disintegrant system
• The generic applicant uses a different excipient composition
• A branded sponsor argues that a formulation limitation is infringed
• The generic applicant designs around the claimed concentration or process
• Dissolution behavior is central to bioequivalence or patent validity

The commercial risk is therefore indirect. An excipient supplier can face discovery requests, technical subpoenas or indemnification discussions, but it is usually the drug-product applicant that bears the principal Paragraph IV exposure.

Patent expiration dates must be assessed drug by drug. There is no single croscarmellose sodium patent-expiration date controlling generic entry across the pharmaceutical market.

What manufacturing and intellectual-property barriers exist?

The basic chemistry is established, which limits the strength of composition-of-matter protection. The most defensible supplier advantages are operational and technical.

Manufacturing barriers

Important barriers include:

• Consistent cross-linking and substitution control
• Reproducible swelling and water-wicking behavior
• Low microbial and endotoxin burden where applicable
• Control of residual reagents
• Particle-size and morphology consistency
• Reliable drying, milling and blending
• Validated cleaning and contamination controls
• Global change-control management

The excipient must perform consistently across different active ingredients and manufacturing processes. A nominally equivalent material may produce different disintegration or dissolution results because of differences in particle size, moisture, morphology or compression behavior.

Intellectual-property barriers

Supplier IP is more likely to cover:

• Manufacturing processes
• Specialized grades
• Particle engineering
• Treatment or modification methods
• Formulation know-how
• Analytical methods
• Application-specific performance data

Trade secrets and customer-specific technical knowledge may be more valuable than patents. A supplier that understands how its grade performs in difficult formulations can retain business even when nominally equivalent products are available.

How does croscarmellose sodium compare with competing superdisintegrants?

Attribute	Croscarmellose sodium	Crospovidone	Sodium starch glycolate
Primary function	Swelling and wicking	Capillary action and porous structure	Strong swelling
Common use	Immediate-release tablets and capsules	Immediate-release and orally disintegrating products	Immediate-release tablets
Typical commercial issue	Grade variability and supplier qualification	Cost and formulation compatibility	Swelling behavior and sensitivity to formulation conditions
Main competitive advantage	Broad use and established regulatory history	Rapid liquid uptake and low gelling tendency	High swelling capacity
Commercial substitution	Often possible after testing	Requires comparative dissolution work	Requires comparative performance and stability work

Substitution is not automatic. Formulators must compare disintegration time, dissolution, hardness, friability, assay uniformity and stability. A lower-priced alternative can create hidden costs if it changes tablet performance or triggers a regulatory supplement.

What licensing deals and partnerships affect croscarmellose sodium?

Publicly disclosed, product-specific licensing deals for croscarmellose sodium are limited. The category is usually commercialized through manufacturing, distribution and technical-service agreements rather than high-value drug-style licenses.

Relevant partnership structures include:

• Regional distribution agreements
• Contract manufacturing
• Dual-source supply arrangements
• Technical qualification programs
• Joint development of engineered excipient grades
• Portfolio transactions involving broader excipient businesses

The most material transaction risk is a change in ownership of a supplier portfolio or manufacturing site. Such changes can require customer notification, regulatory assessment and requalification. Buyers of excipient businesses generally value recurring customer relationships, validated production assets and global regulatory files more than standalone patent rights.

What generic launch scenarios exist?

Croscarmellose sodium creates little direct barrier to generic launch, but it can affect development timing.

Low-risk launch

A generic applicant uses a widely accepted grade, has prior experience with the excipient, and demonstrates comparable dissolution and bioequivalence. The main risks are reference-drug patents and regulatory review.

Moderate-risk launch

The applicant uses a different supplier or grade. Comparative formulation work, stability testing and regulatory documentation become more important. The product may still launch without major delay if performance is equivalent.

High-risk launch

The formulation relies on a narrow disintegrant concentration, unusual particle attributes or a patented excipient combination. The applicant may face formulation redesign, patent litigation or delayed approval.

For most products, croscarmellose sodium is a manageable formulation input rather than a primary generic-entry barrier.

Is there biosimilar risk to croscarmellose sodium demand?

Biosimilars have limited direct impact because most biosimilar products are injectable or parenteral formulations and do not use tablet disintegrants. Growth in biologics can reduce the relative share of oral solid-dose development, but this effect is offset by continued global demand for generic tablets, small-molecule medicines and fixed-dose combinations.

Croscarmellose sodium remains more exposed to oral small-molecule volume than to biologic substitution.

What geographic markets offer the strongest growth?

Region	Market characteristics
North America	High quality requirements, mature generic market, premium on supply reliability
Europe	Strong compendial expectations and established excipient qualification
India	Large generic manufacturing base and export-oriented demand
China	Expanding domestic pharmaceutical production and competitive local supply
Latin America	Growing generic penetration with price-sensitive procurement
Middle East and Africa	Rising access to essential medicines, often dependent on imported excipients

India and China offer the strongest volume potential because of their large generic manufacturing sectors. North America and Europe remain commercially important because customers pay for documentation, consistency and regulatory support. Growth in emerging markets may carry lower average pricing than mature-market sales.

What is the investment and commercial risk profile?

The category has a defensive demand profile but limited explosive upside.

Key positive factors include:

• Recurring use in high-volume generic products
• Low excipient cost relative to drug-product value
• Long customer relationships after qualification
• Broad compatibility with oral solid-dose manufacturing
• Growth in emerging-market tablet production

Key risks include:

• Commodity-style price competition
• Cellulose and energy-cost inflation
• Customer concentration
• Plant outages or contamination events
• Regulatory findings
• Supplier substitution
• Portfolio divestitures
• Reduced oral dosing from biologic adoption
• Excess capacity in regional markets

Revenue exposure is difficult to isolate at the corporate level. Investors should review segment revenue, pharmaceutical-excipient growth, capacity additions, gross-margin changes, raw-material commentary, customer concentration and acquisition strategy. Product-level croscarmellose sodium revenue is generally unavailable in public filings.

Key Takeaways

• Croscarmellose sodium is a mature, recurring-use pharmaceutical excipient for immediate-release tablets and capsules.
• Demand is tied mainly to generic-drug production and oral solid-dose manufacturing.
• Standalone market revenue and supplier profitability are not generally disclosed publicly.
• Volume growth is likely to be moderate, while pricing remains competitive.
• Premium grades can protect margins through performance consistency, technical support and regulatory documentation.
• The excipient has no independent Orange Book exclusivity or universal patent-expiration date.
• Drug-product patents may claim formulations containing croscarmellose sodium, but Paragraph IV risk is usually drug-specific.
• Manufacturing consistency, qualification history and supply reliability are stronger commercial barriers than basic composition patents.
• Biosimilar growth has limited direct impact because biosimilars are predominantly injectable.
• India, China and other emerging markets offer volume growth, while North America and Europe support higher-value regulated sales.

FAQs

Is croscarmellose sodium the same as sodium starch glycolate?

No. Both are superdisintegrants, but they are chemically different materials with different swelling, wicking and formulation behavior. Substitution requires comparative development testing.

Can a generic drug use a different croscarmellose sodium supplier?

Yes, provided the alternative grade meets applicable specifications and produces acceptable quality, dissolution, stability and bioequivalence results. Regulatory reporting may be required depending on the change.

Does croscarmellose sodium affect tablet bioequivalence?

It can. Changes in disintegrant grade, concentration or performance may alter tablet breakup and dissolution. The impact depends on the drug substance and formulation design.

Is croscarmellose sodium suitable for modified-release tablets?

It is used mainly in immediate-release products. Its water uptake and swelling can interfere with controlled-release mechanisms unless the formulation is specifically engineered to accommodate it.

Which commercial factor most strongly protects croscarmellose sodium suppliers?

Validated performance and supply reliability usually provide greater protection than basic patent rights. Once a grade is qualified in a high-volume product, switching can require formulation, stability and regulatory work.

References

1. United States Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary: Croscarmellose sodium monograph. USP-NF.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.

3. U.S. Food and Drug Administration. (2024). Inactive Ingredient Database. FDA.

4. European Medicines Agency. (2017). Guideline on excipients in the dossier for application for marketing authorisation of a medicinal product. EMA.

5. International Council for Harmonisation. (2009). Q8(R2) pharmaceutical development. ICH.

6. International Federation of Pharmaceutical Manufacturers and Associations. (2023). Pharmaceutical excipient quality and supply considerations. IFPMA.